Study Investigating the Role of Routine Screening and Molecular Characterisation of Brain Metastasis in the Management of High-risk Metastatic Breast Cancer

Inclusion Criteria

• •Metastatic breast cancer with visceral, nodal or bone metastasis
• •Human epidermal growth factor type2 (HER2-positive disease)
• •Triple negative breast cancer (TNBC) with metastatic disease
• •Oestrogen Receptor Positive disease (ER-positive disease) after second-line therapy and cyclin dependent kinase 4/6 inhibitors (CDK4/6 inhibitors), plus more than two sites of bone metastasis or visceral metastasis
• •Diagnosis of metastatic disease in the last 3 months and free of symptoms or disease (with brain MRI confirmation) • Medicare Eligible